-

JCOM INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against J2 Global, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against J2 Global, Inc. (“J2” or the “Company”) (NASDAQ: JCOM). This investigation concerns whether J2 has violated federal securities laws and/or engaged in other unlawful business practices.

On June 30, 2020, Hindenburg Research issued a negative report on J2, alleging that “J2’s opaque acquisition approach has opened the door to egregious self-enrichment, which [Hindenburg] approximate totals $117 million to $172 million.” Hindenburg Research alleges that “J2 acquired a newly formed entity based out of its own VP of Corporate Development’s personal residence for an estimated $20 million. The entity had undefined ‘intellectual property’ and no employees or apparent assets. No conflict was disclosed.” The research report also claimed that, “Despite J2’s proxy describing all but one of its board members as ‘independent,’ we found decades of intertwined financial interests between board members and executives, calling that independence into question.”

On this news, the Company’s share price fell $6.29, or 9.1%, to close at $63.21 per share on June 30, 2020.

If you acquired J2 securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:JCOM

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, Vykat XR, as ov...

AGL ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of agilon Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired agilon health, inc. (“agilon” or the “Company”) (NYSE:AGL) securities during the period of February 26, 2025 through August 2, 2025, inclusive (“the Class Period”). If you suffered a loss on your agilon investments, you have until March 2, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS]...

FFIV: Kirby McInerney LLP Advises F5, Inc. Investors of Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased F5, Inc. (“F5” or the “Company”) (NASDAQ:FFIV) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your F5 investments, you have until February 17, 2026 to request lead plaintiff appointment. Follow the link below for...
Back to Newsroom